Ritter Pharmaceuticals (RTTR) Trading Up 5.7%

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was up 5.7% during trading on Wednesday . The stock traded as high as $0.38 and last traded at $0.37. Approximately 841,400 shares were traded during trading, an increase of 111% from the average daily volume of 398,330 shares. The stock had previously closed at $0.35.

Several equities research analysts recently commented on RTTR shares. Zacks Investment Research raised Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Tuesday, September 19th. HC Wainwright reduced their price objective on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research note on Monday, October 23rd. Finally, Roth Capital set a $2.00 price objective on Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $2.10.

The firm has a market capitalization of $17.82 and a P/E ratio of -0.29.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.14). sell-side analysts predict that Ritter Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Susquehanna International Group LLP acquired a new stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned 4.49% of Ritter Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 33.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/17/ritter-pharmaceuticals-rttr-trading-up-5-7.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit